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e.2013.06Abstract Erythropoietin (EPO) is a hematopoietic factor with multiple protective effects. The aim
of the present study was to investigate the potential effect of EPO administration on renal functions
and hypoxia inducible factor 1-alpha (HIF-1a) in diabetic rat kidneys. The current study was car-
ried out on 40 male albino rats divided into four groups (n= 10 in each). Group I served as normal
control, group II was the diabetic control, group III rats received EPO on the same day of diagnosis
of diabetes mellitus (DM), while group IV received the ﬁrst dose of EPO 2 weeks after the diagnosis
of DM. The results showed that EPO supplementation leads to a signiﬁcant decrease in serum urea,
urinary protein and creatinine clearance as well as a signiﬁcant increase in renal HIF-1a in group III
and IV rats compared to the diabetic control group (group II). However, fasting blood glucose was
signiﬁcantly decreased in group III as compared to the diabetic control group in the third week, but
no signiﬁcant difference was reported in the fourth week among groups II, III and IV.
Conclusion: EPO administration leads to the improvement of renal functions and increased levels
of HIF-1a in diabetic rats.
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.0031. Introduction
Diabetic nephropathy (DN) is the most common cause of end
stage renal disease in industrial countries. Proposed mecha-
nisms of DN include hyperglycemia, advanced glycation
end-products (AGE), which increased the permeability of the
basement membrane and reduced the expression of nephrin.1
Hyperglycemia was also found to increase the expression of
transforming growth factor beta (TGF-ß) in the glomeruliand hosting by Elsevier B.V. All rights reserved.
70 A.E. Hassan et al.which may contribute to both the cellular hypertrophy and en-
hanced collagen synthesis observed in DN.2
Messenger RNA encoding the erythropoietin (EPO) recep-
tor has been detected in several tissues including the kidney,
suggesting paracrine extraerythropoietic actions of EPO.3
To protect tissues suffering from hypoxia, cells suppress
protein synthesis and activate other pathways essential to sur-
vival, which results in the expression of genes involved in adap-
tation to hypoxia. Hypoxia inducible factor alpha (HIF-1a) is
an essential corner stone in this adaptive process.42. Materials and methods
After approval of the Ethics Committee of the Faculty of Med-
icine, Alexandria University, this study was carried out on 40
male albino rats weighing 200–250 g. Rats were maintained
under standard conditions with free access to food and water.
Diabetes mellitus was induced in thirty rats by a single intra-
peritoneal injection of Streptozotocin (STZ) (Sigma, Chemi-
cals, St. Louis, MO) in a dose of 55 mg/kg,5 dissolved in
sodium citrate buffer.6 Only rats showing glucosuria
P50 mg/dl by strip (Medi-Test Combi 3A Strips; Germany)
three days after injection of STZ were considered diabetic
and were included in the study.7 No hypoglycemic drugs were
given to the rats during the study period. All animals were
treated in accordance with the Declaration of Helsinki for
treating laboratory animals.
Rats were divided into four groups (10 rats each). Group I
(NormalControl):Non-diabetic rats that received a single intra-
peritoneal dose of solvent (Sodium Citrate, pH = 4.5). Group
II (Untreated diabetic): Diabetic rats were given subcutaneous
injections of saline every 2 days for 2 weeks (a total of 6 injec-
tions) starting the ﬁrst dose on the same day of diagnosis of
DM. Group III (Preventive Diabetic Group): Diabetic rats that
received subcutaneous injections of 100 IU/kg recombinant hu-
man EPO every 2 days for 2 weeks (a total of 6 injections) start-
ing the ﬁrst dose on the same day of diagnosis of DM.Group IV
(Treated Diabetic Group): Diabetic rats showing proteinuria,
were given subcutaneous injections of 100 IU/kg recombinant
human EPO every 2 days for 2 weeks (a total of 6 injections)
starting the ﬁrst dose 2 weeks after diagnosis of DM. The study
period lasted for 4 weeks. The following parameters were mea-
sured weekly:
- Blood glucose level (mg/dl)8 from fresh samples by glucose
oxidase (GOD)-peroxidase (POD) method. (Diamond
Diagnostic; Germany).
- Blood urea level (mg/dl)9 by enzymatic method (modiﬁed
Berthelot reaction) (dp international; Tuscaloosa: USA).
- Creatinine level in blood and urine (mg/dl)10 by a colori-
metric kinetic method (Bio-diagnostic; Paterson, New
Jersey, United States).
- Protein in urine (mg/24 h)11,12 by Folin–Lowry Colorimet-
ric Method (Bio-diagnostic; Paterson, New Jersey, United
States).
In addition, at the end of study period, rats were sacriﬁced
and total Hypoxia Inducible Factor-1 alpha (HIF-1a) was esti-
mated in homogenized renal tissue (pg HIF-1a/mg protein)13
by immunoassay (R&D systems; USA).3. Statistical analysis
Data were collected and analyzed using SPSS software pack-
age version 17. Quantitative data were analyzed using F-test
(ANOVA) to compare between the different groups. Pearson
coefﬁcient was used to estimate the correlation between differ-
ent parameters. P value was assumed to be signiﬁcant 60.05.4. Results
The fasting blood glucose level in groups II, III and IV diabetic
rats was signiﬁcantly higher than in group I control rats in the
ﬁrst week (340 ± 7.04, 310.5 ± 7.12, 310.5 ± 5.56 and
80.4 ± 5.32, respectively) (P= 0.001). However, in the third
week EPO supplementation in group III signiﬁcantly lowered
the fasting blood glucose as compared with group II
(350.00 ± 10.01 and 398.5 ± 17.88 mg/dl) (P= 0.001). In
the fourth week, no signiﬁcance was reported between groups
II, III and IV (Fig. 1).
The serum urea levels in the diabetic control group (group II)
were signiﬁcantly higher than those of group I (normal control)
during thewhole study period,while in group III, serumurea levels
were signiﬁcantly higher than in group I in the 2nd, 3rd and 4th
weeks (22.12 ± 2.95, 25.25 ± 4.76 and 26.33 ± 4.52 mg/dl in
group III versus 19.31 ± 1.12, 20.49 ± 1.85 and 19.60 ±
2.27 mg/dl in group I)with high signiﬁcance detected on the fourth
week (P= 0.006, P= 0.004, P= 0.001, respectively). However,
serum urea levels in group III (20.70 ± 1.19, 22.12 ± 2.95,
25.25 ± 4.76 and 26.33 ± 4.52 mg/dl during the four studied
weeks, respectively) were signiﬁcantly lower than in group II
(27.90 ± 2.92, 33.40 ± 3.10, 40.10 ± 5.70 and 73.07 ±
10.15 mg/dl,P= 0.001). In treated diabetic rats (group IV), serum
urea levels were signiﬁcantly higher than in group I during the four
studied weeks (28.36 ± 5.19, 30.28 ± 11.02, 31.59 ± 12.26 and
32.80 ± 9.68 mg/dl in group IV versus 20.70 ± 1.19,
19.31 ± 1.12, 20.49 ± 1.85 and 19.60 ± 2.27 mg/dl in group I,
P= 0.001, 0.003, 0.006 and 0.001, respectively) and signiﬁcantly
lower than group II in the 3rd and 4thweekswith high signiﬁcance
in the fourth week (P= 0.031 and 0.001, respectively) (Fig. 2).
The urinary protein levels of groups II and IV were signif-
icantly higher than group I during the whole study period. In
group III rats that received EPO for 2 weeks since the diagno-
sis of DM, urinary proteins were signiﬁcantly lower than
group II untreated diabetic rats in the third and fourth weeks
(10.25 ± 5.12 and 12.86 ± 3.46 mg/24 h in group III versus
28.32 ± 5.67 and 40.06 ± 8.86 mg/dl in group II,
P= 0.001). However, in group IV rats that received EPO
two weeks after the diagnosis of DM, urinary protein levels
were signiﬁcantly lower than group II (untreated diabetic) in
the 3rd and 4th weeks only (17.10 ± 0.88 and
20.43 ± 3.48 mg/24 h in group IV versus 28.32 ± 5.67 and
40.06 ± 8.86 mg/24 h in group II, P= 0.001) (Fig. 3).
Creatinine clearance in group II diabetic rats was signiﬁ-
cantly higher than group I rats in the 2nd, 3rd and 4th weeks
(1.41 ± 0.06, 2.09 ± 0.06 and 2.17 ± 0.24 ml/min in group II
versus 1.13 ± 0.04, 1.14 ± 0.19 and 1.04 ± 0.15 ml/min in
group I, P= 0.001). In the preventive diabetic group (group
III), creatinine clearance was signiﬁcantly higher than in group
I mainly in the 3rd and 4th weeks (1.32 ± 0.15 and
1.44 ± 0.07 ml/min in group III versus 1.14 ± 0.19 and
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Figure 1 Fasting blood glucose level (mg/dl) in the different studied groups.
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Figure 2 Serum urea levels in (mg/dl) in the different studied groups.
Effect of erythropoietin hormone supplementation on renal functions and the level of hypoxia-inducible factor-1a 711.04 ± 0.15 ml/min in group I, P= 0.014) with high signiﬁ-
cance detected in the fourth week (P= 0.001). However, in
the 2nd, 3rd and 4th weeks, the creatinine clearance level
was signiﬁcantly lower in group III (1.12 ± 0.05, 1.32 ± 0.15
and 1.44 ± 0.07 ml/min) than in group II (1.41 ± 0.06,
2.09 ± 0.06 and 2.17 ± 0.24 ml/min) and group IV rats
(1.41 ± 0.21, 1.63 ± 0.22 and 1.63 ± 0.13 ml/min
(P= 0.001). In treated diabetic group (group IV), creatinine
clearance level was signiﬁcantly lower than the diabetic control
group in the 3rd and 4th weeks (P= 0.001) (Fig. 4).
HIF-1a in renal tissue showed a highly signiﬁcant increase
4 weeks after the induction of diabetes in groups II, III and IV
(114.04 ± 31.58, 547.86 ± 218.23 and 380.30 ± 101.27 pg/mg
protein, respectively) when compared to the normal control
group I (26.38 ± 8.78 pg/mg protein) (P= 0.001). However,erythropoietin-supplied groups (preventive group III and trea-
ted diabetic group IV) showed signiﬁcantly higher levels than
the diabetic control group (P= 0.001). Group III rats re-
ported a signiﬁcantly higher level of HIF-1a than group IV
(p= 0.02) (Fig. 5, Table 1). See (Fig. 6, Table 2).
5. Discussion
Diabetes mellitus (DM) is a chronic disease resulting in multi-
ple complications, including nephropathy.14 Numerous studies
reported the association of DM with several changes in the
structure and function of the kidney.15 Strict control of blood
glucose and blood pressure levels sometimes fail to delay the
development of diabetic nephropathy (DN), and an effective
therapy is not yet available.16
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Figure 3 Protein in urine (mg/24 h) in the different studied groups.
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Figure 4 Creatinine clearance (ml/min) in the different studied groups.
72 A.E. Hassan et al.In the present study, the fasting blood glucose level was sig-
niﬁcantly higher in groups II, III and IV than in group I rats
throughout the study period. This is explained by the cytotoxic
effect of streptozotocin on beta cells of the islets of Langer-
hans, liberation of free radicals and toxic amount of nitric
oxide causing necrosis of these cells.17 Moreover, in the third
week of the study, a signiﬁcant decrease was noticed in the pre-
ventive group (III) as compared with the diabetic control
group (II), however no signiﬁcant change was reported in the
fourth week between groups III and IV. This hypoglycemic ef-
fect in group III in the third week may be explained by the in-
crease in the erythrocyte counts and their consequent uptake
of glucose previously reported by Montel-Hagen et al.18 An-
other work that supports the previous result reported an in-
crease in the circulation volume of total red blood cells after
twelve days of recombinant erythropoietin injections intonephrectomized rats.19 By the fourth week, no signiﬁcant dif-
ferences were reported among groups II, III and IV. The pos-
sible reason for this was that the beta cells have already been
destroyed by streptozotocin and the possible improvement of
the function of the remaining beta cells was not sufﬁcient to re-
turn the blood glucose level to the normoglycemic state in spite
of the antioxidant effect of erythropoietin.20 Similar results
were reported by other researchers who found that after 5, 8,
or 11 weeks, all diabetic rats remained hyperglycemic, and
EPO treatment did not signiﬁcantly affect blood glucose lev-
els.21 Katz et al.22 reported that after one week of treatment,
all EPO-treated mice had lower blood glucose levels, and these
levels were further reduced during the second week of treat-
ment, which may be explained by the reduction of insulin resis-
tance; as EPO increased sensitivity to insulin and also the beta
cells were not yet totally destroyed.22
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Figure 5 Hypoxia inducible factor 1-alpha (HIF-1a) levels (pg/mg protein) in the different studied groups.
Figure 6 Correlation between HIF-1a and glucose in all groups.
Effect of erythropoietin hormone supplementation on renal functions and the level of hypoxia-inducible factor-1a 73In the present study, group II diabetic rats showed a signif-
icantly higher rate of urinary protein excretion one week after
the onset of the diabetes when compared with values of normal
control rats. Proteinuria progressively increased throughout
the whole length of the study period, with maximal levelTable 1 Hypoxia inducible factor 1-alpha (HIF-1a) level (pg/mg p
Treated diabetic (group IV) Preventive diabetic (gro
HIF-1a
Min–Max 179.2–568 303.77–992
Mean ± SD 380.30 ± 101.27 547.86 ± 218.23
P1 0.001b
P2 0.001b
P3 0.001b
P4 0.001b
P5 0.001b
P6 0.020a
P1 comparison between normal control group I and diabetic control gro
a Signiﬁcant at P 6 0.05.
b Highly signiﬁcant at P 6 0.001.reached at the end of the fourth week. Ronchi et al.23 reported
that diabetic rats showed a signiﬁcant increase in the excretion
of urinary proteins starting as early as 24 h after the induction
of DM, which may be related to glomerular dysfunction and
damage, while Farvid et al.24 postulated that proteinuria pre-
dicted the onset of overt renal disease in diabetic patients.
While, in the third and fourth weeks, groups III and IV
showed signiﬁcantly decreased levels of proteinurea than
group II. This is in accordance with the results obtained by
Zaﬁrov et al.25 who explained reduced proteiurea by the reno-
protective effect of recombinant human erythropoietin mani-
fested by the stimulation of tubular cell proliferation and
regeneration, thus reducing the functional renal failure and re-
nal damage induced by cisplatin.25
Moreover, in this study, serum urea level in the preventive
diabetic group III rats was signiﬁcantly lower than the diabetic
control group during the four studied weeks. On other hand, in
the treated diabetic group IV rats, serum urea level was signif-
icantly lower than the diabetic control group in the 3rd and 4th
week, with high signiﬁcance in the fourth week. This denotes
improvement of renal function in rats that received EPO. Sim-
ilar observations were reported by Toba et al.26 who demon-
strated direct reno-protective effects of chronic treatment
with low dose of recombinant human EPO (150 IU/kg threerotein) in the different studied groups.
up III) Diabetic control (group II) Normal control (group I)
81.9–175.1 11.7–40.5
114.04 ± 31.58 26.38 ± 8.78
up II.
Table 2 Correlation studies.
HIF Serum urea Protein
in urine
Fasting
glucose
Creatinine
clearance
R .234 .040 .413(**) .033
P .146 .808 .003 .839
74 A.E. Hassan et al.times per week subcutaneously), which included decreased
proteinuria and slowing of renal dysfunction and ﬁbrosis in
the streptozotocin-induced diabetic rats models.
Several studies reported that preconditioning the kidney
with EPO before ischemia reperfusion injury protects the kid-
ney.27,28 Menne et al.21 provided evidence that continuous
erythropoietin receptor activator (CERA) may exert dose
dependent protective effect on diabetic kidneys, decreased
albuminuria, reduced expression of TGF-beta, decreased vas-
cular endothelial growth factor, and reduced deposition of col-
lagen IV in the glomeruli and tubulointerstitial area.
Overexpression of TGF-B1 is harmful as it stimulates podo-
cyte expression of collagen IV, podocyte detachment and/or
apoptosis.29,30
Binding of EPO to its receptor triggers the activation of sig-
nal transducer and activator of transcription (STAT) 5 pro-
teins, which enters the nucleus, and enhances the
transcription of various genes. In fact, EPO may act as a sur-
vival factor by inhibiting apoptosis through the anti apoptotic
molecule Bcl-x(L), an anti-apoptotic protein of the Bcl-2 fam-
ily. Yang et al.27 showed that EPO also induces heat shock
protein 70 which possesses antiapoptotic effect by the inhibi-
tion of apoptosis protease-activating factor-1 and of apopto-
sis-inducing factor.
In the current work, creatinine clearance was signiﬁcantly
increased in group II than the control group in the second,
third and fourth weeks, this may be due to hyperﬁltration
which is widely regarded as a contributing factor to the devel-
opment of microalbuminuria and progressive nephropathy in
type 1 diabetes.31
Creatinine clearance was signiﬁcantly lower in diabetic rats
that received EPO since the diagnosis of DM (group III) than
untreated group II rats. This is also most probably due to the
protective antiapoptotic effect of EPO.27 In group IV, creati-
nine clearance decreased signiﬁcantly compared with group
II. This may be explained by the hypothesis that EPO was
found to decrease the glomerular ﬁltration rate documented
in humans.32
Hypoxia inducible factor-1a (HIF-1) is a transcriptional
factor responsible for cellular adaption to low oxygen tension.
It regulates a group of genes involved in angiogenesis, iron
metabolism, glucose metabolism as well as cellular prolifera-
tion and survival.33
In this study, HIF-1a levels showed a signiﬁcant increase
4 weeks after the induction of diabetes in groups (II, III and
IV) when compared to the normal control group (I). However,
erythropoietin-supplied groups (preventive group III and trea-
ted diabetic group IV) had signiﬁcantly higher levels than the
diabetic control group. This coincides with the ﬁndings of
other researchers that detected renal HIF- alpha in the glome-
ruli of rats 30 days after the induction of DM.34
In the current study, a signiﬁcant positive correlation was
observed in all the studied groups between blood glucose levels
and renal HIF-1a levels. A recent study reported that high glu-cose exposure induced the production of reactive oxygen species
(ROS) and, in parallel, induced glucose 6 phosphatase (G6pc)
promoter activity. This, in turn, increased glucose release from
hepatocytes. This recent study by Gautier-Stein et al. deci-
phered a new regulatory mechanism leading to the induction
of HIF-1 transcriptional activity which may contribute to the
increase of hepatic glucose production during diabetes.35
The current data show a delayed onset of nephropathy in
diabetic rats which received erythropoietin immediately on
the diagnosis of DM (preventive diabetic group). This was
manifested by lower urinary protein levels, serum urea and
higher creatinine clearance. The results also show the slower
progression of nephropathy in diabetic rats that received
EPO 2 weeks after the appearance of proteinuria (treated dia-
betic group). However, urinary protein levels and serum urea
levels are much better in the preventive group than the treated
group at the end of study. The reno-protective effect of eryth-
ropoietin may be due to increased levels of HIF-1a, with its
speciﬁc target genes that ﬁght oxidative stress, ameliorate
blood oxygen, glucose supply and block apoptotic pathways.33
Imamura et al.36 also conﬁrmed the reno-protective effects
of EPO treatment in ischemia reperfusion injury (I/R) by the
induction of both HIF-1 alpha and vascular endothelial
growth factor mRNA under hypoxic conditions, through
attenuation of tubular hypoxia. Moreover, erythropoietin
could enhance eNOS expression via HIF-2 activation.37 Re-
cent studies have also revealed that EPO suppresses the up-reg-
ulated expression of TGF-b, and may possibly improve the
accumulation of extracellular matrix.38,39
The protective effects of erythropoietin on tubulointerstitial
ﬁbrosis are supported by decreased renal ﬁbrosis in mice by
inhibiting TGF-b.38 Lastly, it has recently been demonstrated
that EPO directly ameliorates podocyte injury resulting in
the prevention of glomerulosclerosis.40
The results of the current study suggest that prophylactic
EPO administration in diabetic rats is more beneﬁcial than
its administration 2 weeks after the induction of DM. These
reno-protective effects of EPO are related to increasing the lev-
els of hypoxia inducible factor-1a. In fact, kidneys of diabetic
rats are hypoxic even at an early stage, HIF activation is nei-
ther maximal in kidney disease nor in diabetic conditions not
receiving EPO.34
However, further studies are needed to estimate the proper
timing and dosage for EPO administration to maximally stim-
ulate the expression of HIF-1a and delay the occurrence of
diabetic nephropathy.
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